- Home
- ZYBT vs SCLXW Comparison
ZYBT vs SCLXW Comparison
Compare ZYBT & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYBT
- SCLXW
- Stock Information
- Founded
- ZYBT 2004
- SCLXW N/A
- Country
- ZYBT China
- SCLXW United States
- Employees
- ZYBT N/A
- SCLXW 115
- Industry
- ZYBT
- SCLXW Biotechnology: Pharmaceutical Preparations
- Sector
- ZYBT
- SCLXW Health Care
- Exchange
- ZYBT NYSE
- SCLXW Nasdaq
- Market Cap
- ZYBT N/A
- SCLXW N/A
- IPO Year
- ZYBT 2025
- SCLXW N/A
- Fundamental
- Price
- ZYBT $10.44
- SCLXW $0.09
- Analyst Decision
- ZYBT
- SCLXW
- Analyst Count
- ZYBT 0
- SCLXW 0
- Target Price
- ZYBT N/A
- SCLXW N/A
- AVG Volume (30 Days)
- ZYBT 556.2K
- SCLXW 4.0K
- Earning Date
- ZYBT 01-01-0001
- SCLXW 03-07-2025
- Dividend Yield
- ZYBT N/A
- SCLXW N/A
- EPS Growth
- ZYBT N/A
- SCLXW N/A
- EPS
- ZYBT 0.06
- SCLXW N/A
- Revenue
- ZYBT $26,111,272.00
- SCLXW $55,152,000.00
- Revenue This Year
- ZYBT N/A
- SCLXW N/A
- Revenue Next Year
- ZYBT N/A
- SCLXW N/A
- P/E Ratio
- ZYBT $170.78
- SCLXW N/A
- Revenue Growth
- ZYBT N/A
- SCLXW 22.02
- 52 Week Low
- ZYBT $3.50
- SCLXW $0.18
- 52 Week High
- ZYBT $12.46
- SCLXW $0.18
- Technical
- Relative Strength Index (RSI)
- ZYBT N/A
- SCLXW N/A
- Support Level
- ZYBT N/A
- SCLXW N/A
- Resistance Level
- ZYBT N/A
- SCLXW N/A
- Average True Range (ATR)
- ZYBT 0.00
- SCLXW 0.00
- MACD
- ZYBT 0.00
- SCLXW 0.00
- Stochastic Oscillator
- ZYBT 0.00
- SCLXW 0.00
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.